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Abstract
Background National guidelines recommend bisphospho-
nates for secondary prevention of osteoporotic fractures;
however, poor compliance may result in sub-optimal
prevention.
Objective This study reports the feasibility of using GP elec-
tronic records to identify poorly compliant post-menopausal
women who may be at increased risk of fragility fractures.
Design Cross-sectional study of general practice computer
records.
Subjects Women over 45 years, registered in 29 practices
across England with a total population of approximately
200,000.
Methods MIQUEST (Morbidity Information Query and
Export Syntax) a data extraction application was used to
extract prescription, diagnostic data and probable fragility
fractures (hip, vertebral, wrist). All women >45 years who
received a first prescription for a weekly bisphosphonate
(alendronate or risedronate) at least a year before data
extraction were identified. Each record was examined to
determine the number of days of prescribed treatment.
Results Of 97992 registered women, 44% (42734) were
>45 years. Prevalence of likely fragility fractures in women
over 45 was 5.1% (2195/42734). 3.0% (1286/42734, mean
age 72 years) received a prescription for a bisphosphonate
in the 360 day period prior to data extraction with a median
duration of treatment of 267 days. 45% (584/1286) received
prescriptions covering >288/360 days (Medicine Possession
Ratio >80%); 13% (161/1286) collected prescriptions
covering >360 days. In those prescribed bisphosphonates,
23% (294/1286) had a likely fragility fracture.
Conclusions Women >45 years with probable fragility frac-
tures are more likely to be prescribed bisphosphonates, though
less than half will be actually taking them as prescribed. GPs
should use computer technology to identify poorly compliant
patients who are unnecessarily at risk of fracture.
Keywords Biphosphonates . Computerised . Fractures .
Medical records systems . Osteoporosis . Patient
compliance . Postmenopausal . Spontaneous . Treatment
refusal
Key Points
– Recorded prevalence of likely fragility fracture in
women >45 years is 5.1%
– Women >45 years with a likely fragility fracture are
more likely to be prescribed a bisphosphonate.
– Less than half of women >45 years (45%) prescribed a
bisphosphonate have collected a complete set of
bisphosphonate prescriptions for their last year of
therapy and the rate was not significantly different
(42%) in women >45 yrs with a likely fragility fracture.
– About 1 in 8 (13%) are collecting an excess number of
prescriptions.
– Computer searches would allow women who are likely
under and over-users of bisphosphonates to be identi-
fied. A starting point might be those with existing
likely fragility fractures.
Introduction
Bisphosphonates reduce the fracture risk in postmenopausal
women with osteoporosis; however, compliance to therapy
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is poor, putting patients at risk. Bisphosphonates are known
to increase bone mineral density (BMD) in the lumbar spine
and hip and this appears to be clinically significant, in that
new vertebral fractures, non-vertebral fractures and hip
fracture rates are all reduced [1–4]. However, compliance
with bisphosphonates is known to be poor [5, 6]. Further,
poor compliance translates into reduced bone mineral
density (BMD) [7] increased hospitalisation and fracture
rates [8, 9]. Compliance can be quantified using the
medicines possession ratio (MPR); the ratio of the number
of days' supply to the length of the study period. For
bisphosphonates an MPR under 80% is associated with
increased fracture risk [8, 10].
The UK national guidelines recommend the use of
bisphosphonates for the secondary prevention of fragility
fractures in women with osteoporosis [11]. The guidance
recommends the use of bisphosphonates in women 75 years
and over, who have had a fracture without the need for
measurement of BMD for those between 65 and 74 after
measurement of BMD and in younger women if they have
additional risk factors. In theory these patients should be
easy to find from general practice computer records.
Although computerisation is ubiquitous in UK general
practice, osteoporosis data recording is variable [12].
Repeat prescribing data are generally complete and reliable
[13]. However, in osteoporosis, diagnostic data are poor
and there are technical problems which prevent the easy
recording of dual X-ray densitometry (DXA) scan results
[14].
We carried out this study to investigate the feasibility of
using routinely collected computer data to improve the
quality of care for people with osteoporosis and help
practices implement the new national guidelines. We
decided to test the feasibility of identifying women who
do not persist with bisphosphonate therapy, especially those
with a likely fragility fracture or a pre-existing computer
diagnosis of osteoporosis.
Method
We recruited a sample from practices who had participated
previously in PCDQ (Primary Care Data Quality) pro-
grammes [15, 16]. We excluded practices who had been
involved in previous PCDQ osteoporosis studies [12, 17] as
this may have improved their osteoporosis computer data
quality and we wanted our sample to be as representative as
possible of “usual” UK practice. We invited practices from
the north east and north west of England, London and the
south east. We collected these data between March and
May 2005.
We defined the dataset needed to answer our research
question. The elements of the dataset were: demographic
details, fracture recording, use of therapy to treat or
prevent osteoporosis and the last twelve bisphosphonate
prescriptions.
We used an established methodology to extract, aggre-
gate, process, clean and analyse these data [18, 19]. We use
MIQUEST (Morbidity Information and Export Syntax), a
Department of Health sponsored data extraction application
to extract anonymous data from general practice computer
systems [20].
We analysed the age-sex distribution of the population
and compared it to the 2001 census population so that we
could standardise prevalence rates. We analysed in detail
data for women >45 years, in line with other investigators
methods [21, 22].
We looked at the types and age-distribution of fracture
recording. We made the assumption that all fractures of
wrist, hip and spine occurring over age 45 years were likely
to be fragility fractures. We also included codes for fragility
fracture. We separately searched the different sections of
the clinical coding hierarchy (the UK uses Read codes) to
identify the relevant events.
We identified the types of therapy prescribed for
osteoporosis, including hormone replacement therapy;
though recognising that the latter has a wide range of other
indications. We included prescription data for any
bisphosphonates with a licence for the treatment of
osteoporosis. For technical reasons our extraction included
pamidronate, ibandronate, clodronate and zoledronate,
because these are included in the bisphosphonate coding
hierarchy. These drugs are indicated for treatment of the
pain from bone secondary cancer, they were excluded from
our results. However, one of these, ibandronate, was in the
process of obtaining a product licence for the treatment of
osteoporosis. As none of the small number of patients on
ibandronate had been prescribed over a year’s therapy they
were excluded from our results.
Finally, we examined the compliance with weekly
bisphosphonates, alendronate and risedronate, over a one-
year period. We did this by analysing the last 12
prescriptions issued. Our previous studies indicated that
these medications were never prescribed for less than one
month and usually for two to six months at a time [12, 17].
We therefore felt that collecting data about the last 12
prescriptions would ensure we had data for at least a year.
We set a cut off that all of these 12 prescriptions must have
been issued more than 180 days (six months) before the
data were extracted, so we would most likely capture
fracture data recorded later when hospital discharge
information came through.
We used the SPSS (Statistical Package for Social Sciences)
to measure the number of days of therapy prescribed in the
latest year of therapy. All the quantity elements were
converted into the number of days of therapy. We did this by
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converting one “original pack” into the pack size defined in
the British National Formulary and converting this into day
therapy. The SPSS vector command was used to reorder the
triplet of information we held about each prescription (drug
code, date and quantity). The days prescribed for each patient
for the time period between 18 months before (420 days) and
six months (180 days) before data collection were then
calculated.
We then calculated the percentage of people who
complied for 12 months the median duration of therapy of
those who did not persist for 12 months and the percentage
of patients with a medicine possession ratio (MPR) of less
than 80% (i.e., they collected prescriptions for less than
80% of a year:<288 days). To see if there was any
relationship between compliance and a previous fragility
fracture, we subsequently looked at the categories of
compliance. Compliance of <50% is described as poor,
50–79% medium, 80–90% good, >90% excellent.
Finally, we looked to see whether a greater or lesser
proportion of women >45 years with likely fragility
fractures were persisting with their bisphosphonate therapy
and whether people with multiple fractures were more
likely to be compliant.
Statistical methods Mean is used to describe normally
distributed variables, median and interquartile ranges
(IQR) to describe variables which are not normally
distributed. Chi-square (X2) tests were performed to
determine whether any changes in proportion were statis-
tically significant.
Ethics Central ethics approval was granted for this study.
Results
Our sample had an age-sex profile close to the national
average. The combined population from 29 practices was
195,910. The practices range in size from 1,817 to 13,693
(mean list size 6,756, median 7,127, IQR 2,325). Osteopo-
rosis diagnosis recording rate was 1.08% (n=2,107), with a
male-female recording ratio of 1:8 (males n=230; females
n=1,877).
In women over 45 years old (n=42,734), the recorded
prevalence was 4.31% (n=1,843). The standardised
recorded prevalence of a diagnosis of osteoporosis using
the 2001 census was 1.03%. The recorded prevalence of
osteoporosis was variable between practices the preva-
lence varied from 0.00% to 2.50%, (median 0.93% IQR
0.74%).
The recorded prevalence of fractures increased with age.
In males it was higher in younger men, but the converse
applied in older women. The recording of fractures in males
under 45 years had a higher fracture rate than females (M
<45 yrs 1.67%; F <45 yrs 1.05%), but in women over
45 years old the prevalence of fractures is much greater (M
≥45 yrs 3.39%; F≥45 yrs 5.90%), these differences in
proportion are statistically significant (Chi-square test
p<0.001). The difference in fracture rates gets larger with
increasing age (Table 1).
A wide range of therapies for osteoporosis are used in
the study practices and the numbers prescribed treatment
greatly exceed the numbers with a diagnosis of osteoporosis
(n=2,107). Therapies used include hormone replacement
therapy (HRT; n= 9,865), calcium and vitamin D (n=4,771),
bisphosphonates (n=2,977), selective estrogen receptor
modulators (SERM; n=252) and calcitonin (n=20). The
female to male ratio of drug therapy was 13:1 (Female
16614, Male 1271) (Table 2).
The weekly formulations of the bisphosphonates, alen-
dronate and risedronate account for the majority of current
therapy. We found that about half as many patients had
been on daily formulations of bisphosphonates, compared
with the weekly formulations (daily n=907, weekly
n=2,064). However, a small proportion of the people
persisted in taking a daily bisphosphonate, 11.26% (262/
2326), at the end of the study.
Table 1 Age-sex profile of fracture recording
Male Female
Age n Fracture recording Fracture prevalence n Fracture recording Fracture prevalence
0–29 34881 447 1.28% 33065 296 0.90%
30–39 15198 331 2.18% 14480 178 1.23%
40–49 15709 384 2.44% 14585 232 1.59%
50–59 12586 374 2.97% 12471 247 1.98%
60–69 9789 325 3.32% 9949 471 4.73%
70–79 6636 269 4.05% 7574 719 9.49%
80–89 2726 150 5.50% 4627 702 15.17%
90+ 393 31 7.89% 1241 257 20.71%
Total 97918 2311 2.36% 97992 3102 3.17%
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Bisphosphonates which at the time of the study were
not indicated for use in osteoporosis (clodronate, pami-
dronate, ibandronate, tiludronate and andzoedronate)
accounted for less than 1% of prescriptions for
bisphosphonates.
3.0% (1286/42734, mean age 72 years, IQR 17 years)
received a prescription for a weekly bisphosphonate in the
360-day period prior to data extraction with a mean
duration of treatment 231 days, median duration of
treatment, 267 days, 25%tile 112 days, 75%tile 336 days,
IQR 224 days). In females over 45 years (n=42,734)
approximately three times as many were taking weekly
alendronate (n=1,297; 3.0%) compared with risedronate
(n=458; 1.1%).
1,286 patients had 12 or more prescriptions for (alen-
dronate 959, risedronate 327; ratio 2.93:1). For these 1,286
individuals we could calculate a medicines possession ratio
(MPR). We found that 45% (584/1,286) had an MPR ≥80%
who we labelled “compliant”. A slightly higher proportion
of those taking alendronate (47.0%, 451/959) were compli-
ant compared with risedronate (40.7%, 133/327); these
differences are of borderline significance (Pearson Chi-
square: p=0.046.) We also noted that some women
collected too many prescriptions. 27.6% (161/584) collect-
ed excess prescriptions and that 3.6% (21/584) had an MPR
of over 120%.
The level of compliance was not evenly spread across
the four categories of compliance. Most women either had
excellent compliance (MPR >90%) or poor compliance
(MPR <50%), with relatively few in the medium (MPR 50–
79%) or good (MPR 80–90%) category (Fig. 1). We found
a similar pattern in men (data not shown).
Females over 45 years with a recording of a fracture are
no more likely to be compliant with their weekly
bisphosphonate therapy (alendronate or risedronate) than
those without a fracture. 23% (294/1,286) of compliant
people have had fracture; the compliant group have a
fracture rate of 21% (123/584) compared with 24% (171/
702) in the non-compliant group. These proportions are
not significantly different (Pearson Chi-square =0.16).
Multiple fractures were also not associated with improved
compliance with bisphosphonates, it appears that women
were generally poor or excellent in complying with
therapy with relatively few in the intermediate groups
(Fig. 1).
A fracture was found to be recorded in 27% (183/684) of
the people with a diagnosis of osteoporosis who were also
prescribed a weekly bisphosphonate. Those with a diagno-
sis of osteoporosis are much more likely to have fracture
than those who have not (27% compared with 19%) and
this difference in proportion is statistically significant (Chi-
square p<0.001).
Table 2 Age-sex profile of the use of osteoporosis therapies
Age Sex Profile-Osteoporosis medication
Male Hormone replacement
therapy
Calcium and Vitamin D Bisphosphonate Selective estrogen receptor
modulator
Calcitonin
Age bands n n n n n
0–29 5 81 7 0 0
30–39 3 41 11 1 0
40–49 5 47 21 0 0
50–59 6 83 47 0 1
60–69 4 157 111 0 1
70–79 3 218 130 0 2
80–89 2 155 82 0 1
90+ 0 30 16 0 0
Total 28 812 425 1 5
Female Hormone replacement
therapy
Calcium and Vitamin D Bisphosphonate Selective estrogen receptor
modulator
Calcitonin
Age bands n n n n n
0–29 60 102 5 0 0
30–39 168 130 15 0 0
40–49 990 256 70 8 0
50–59 4010 499 299 55 0
60–69 3413 766 595 85 3
70–79 999 1016 814 79 4
80–89 180 908 634 24 6
90+ 17 282 120 0 2
Total 9837 3959 2552 251 15
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Based on these results a practice of 10,000 list size
looking to implement national guidance on osteoporosis
would expect to find:
– 37 post menopausal women who are not compliant to
therapy (MPR <80%) and one post menopausal women
using too much medication.
– Nine women over 45 with a fracture who are not
compliant to bisphosphonates; three of whom would be
aged 65 to 74 and five 75 years or older.
– Computer searches also identified 96 women over 45
with fractures not taking bisphosphonates of who 22
are 65 to 74 and 46 are 75 and older.
– 24 of the women over 45 who have a fracture and are
not taking a bisphosphonate have a computer diagnosis
of osteoporosis, six of these are 65 to 74 and 14 are 75
and over.
Discussion
Principal findings
There is scope to improve the general practice management
of osteoporosis by identifying non-compliant patients using
computer searches. Many patients’ quality of care falls
outside national guidelines. Less than half of women
prescribed bisphosphonates collect sufficient prescriptions
to be compliant with their therapy. We also noted that a
proportion collect too many prescriptions. People who have
had a fracture recorded are no more likely to be compliant
with their therapy than those without a fracture and multiple
fractures make patients no more likely to comply. Computer
data has the potential to identify people with osteoporosis
who are not compliant to therapy. The numbers of people
identified by such searches are probably manageable within
general practice.
Implications for practice
Practices could use computer searches to identify their non-
compliant patients and those who are apparently collecting
too many scripts. Additional input may lead to improve-
ment in compliance to therapy. This might take the form of
a telephone consultation, a nurse visit, or a review by a
pharmacist as part of a medicines management programme
or a consultation with their general practitioner. This
approach could also be used as a method to implement
national guidance on the secondary prevention of fractures
in osteoporosis [11]. Practices with poor data quality should
improve their diagnostic recording and see that fractures are
coded and entered into the computer record.
Limitations of the study
Osteoporosis diagnostic data remains incomplete and it is
likely that fracture recording remains an under-estimate of
true prevalence. Our assumptions that women over 45 years
are “postmenopausal” and fractures in older women are likely
to be osteoporotic are inevitably oversimplifications. Sanders
et al. found that only 71% and 80% of pelvic and hip fractures,
respectively, were truly osteoporotic [23]. The study was also
limited by our ability to only extract structured data and the
confused way that fractures and any DXA scan results are
stored within the clinical record. We only looked at the
structured or “coded” data in the clinical computer record.
We did not extract free text or check any paper notes,
hospital letters or reports. The clinical coding system has
limitations: no codes for “fragility fracture” exist and it is
impossible in the most used clinical computer system to
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enter negative numbers-making any recording of “T-scores”
impossible to interpret as they are all positive numbers [12,
14]. This method may have overestimated the level of
compliance, as we cannot be certain that the medications
prescribed were actually taken. We did not investigate HRT
compliance because this therapy has a range of indications
other than the treatment of osteoporosis.
Comparison with the literature
Poor compliance is a problem with many long-term medi-
cations and there is no single effective strategy to overcome
this. Monitoring use of therapy, reminders to collect prescrip-
tions and reducing the frequency of dosage have all been
shown to be useful, but none provide the complete solution to
this problem [24, 25]. Others have found similarly poor
levels of compliance to bisphosphonate therapy [8]. Osteo-
porosis and occurrence of fractures are under-recorded
compared to rates recorded in the literature [26–28] this is
likely due to poor computer data quality [12, 14, 17].
It is possible that including practices in a feedback loop
will prove as effective in raising standards in this area as we
have found in heart disease [16].
Call for further research
Studies are needed to develop interventions that result in
improvements in data quality and the quality of care in
osteoporosis. Further studies, with more complete datasets,
are needed to evaluate whether there truly are differences in
compliance between the different bisphosphonates.
Conclusions
Whilst computer searches will not identify everyone who
might benefit from bisphosphonate therapy, they enable a start
to be made on identifying a high risk population and imple-
menting national guidelines. A pragmatic place to start im-
proving the quality of osteoporosis management would be to
utilise existing information technology to find non-compliant
patients; especially those who have pre-existing fractures.
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